Patents by Inventor Ralph Brueckner

Ralph Brueckner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240049719
    Abstract: The present invention relates to an antimicrobial coating of a substrate, the coating being obtained by applying the coating on a surface of the substrate by means of an electrostatic spraying method, and the coating comprising at least one metal oxide and/or at least one metal salt. Furthermore, the present invention relates to an electrostatic spraying method for coating at least one substrate with an antimicrobial coating. In addition, the present invention relates to a use of a coating material for producing an antimicrobial coating on a surface of a substrate, with the coating comprising at least one metal oxide and/or at least one metal salt.
    Type: Application
    Filed: October 23, 2023
    Publication date: February 15, 2024
    Inventor: Ralph BRUECKNER
  • Publication number: 20200267990
    Abstract: The present invention relates to an antimicrobial coating of a substrate, the coating being obtained by applying the coating on a surface of the substrate by means of an electrostatic spraying method, and the coating comprising at least one metal oxide and/or at least one metal salt. Furthermore, the present invention relates to an electrostatic spraying method for coating at least one substrate with an antimicrobial coating. In addition, the present invention relates to a use of a coating material for producing an antimicrobial coating on a surface of a substrate, with the coating comprising at least one metal oxide and/or at least one metal salt.
    Type: Application
    Filed: September 12, 2018
    Publication date: August 27, 2020
    Inventor: Ralph BRUECKNER
  • Patent number: 8916548
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: December 23, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Ralph Brueckner, Dirk Kessler, Oliver Kraemer, Darryl McConnell, Siegfried Schneider, Lars van der Veen
  • Publication number: 20130281429
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • Patent number: 8258129
    Abstract: The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are as defined in the disclosure, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: September 4, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel
  • Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Publication number: 20110281838
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: July 28, 2009
    Publication date: November 17, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias Wunberg, Ralph Brueckner, Dirk Kessler, Oliver Kraemer, Darryl McConnell, Siegfried Schneider, Lars van der Veen
  • Publication number: 20110251174
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • Publication number: 20100113414
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo BETZEMEIER, Trixi BRANDL, Steffen BREITFELDER, Ralph BRUECKNER, Thomas GERSTBERGER, Michael GMACHL, Matthias GRAUERT, Frank HILBERG, Christoph HOENKE, Matthias HOFFMANN, Maria IMPAGNATIELLO, Dirk KESSLER, Christian KLEIN, Bernd KRIST, Udo MAIER, Darryl McCONNELL, Charlotte REITHER, Stefan SCHEUERER, Andreas SCHOOP, Norbert SCHWEIFER, Oliver SIMON, Martin STEEGMAIER, Steffen STEURER, Irene WAIZENEGGER, Ulrike WEYER-CZERNILOFSKY, Andreas ZOEPHEL
  • Patent number: 7691888
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 6, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Publication number: 20090203673
    Abstract: The present invention encompasses compounds of general Formula (I) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: July 5, 2007
    Publication date: August 13, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel
  • Publication number: 20070088051
    Abstract: The invention relates to indolinone compounds of formula (I), wherein Y and R1 to R8 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
    Type: Application
    Filed: November 13, 2006
    Publication date: April 19, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Steffen Steurer, Ralph Brueckner, Bernd Krist, Bodo Betzemeier, Frank Hilberg, Armin Heckel, Gerald Roth, Joerg Kley, Thorsten Lehmann-Lintz
  • Publication number: 20070032514
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 8, 2007
    Inventors: Stephan Zahn, Guido Boehmelt, Andreas Mantoulidis, Ulrich Reiser, Matthias Treu, Ulrich Guertler, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Ralph Brueckner, Charlotte Reither, Lars Herfurth, Oliver Kraemer, Heinz Stadtmueller, Harald Engelhardt
  • Publication number: 20070004684
    Abstract: The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 8, 2006
    Publication date: January 4, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Sennhenn, Andreas Mantoulidis, Matthias Treu, Ulrike Tontsch-Grunt, Walter Spevak, Darryl McConnell, Andreas Schoop, Ralph Brueckner, Albrecht Jacobi, Ulrich Guertler, Gisela Schnapp, Christian Klein, Frank Himmelsbach, Alexander Pautsch, Bodo Betzmeier, Lars Herfurth, Juergen Mack, Dieter Wiedenmayer, Gerd Bader, Ulrich Reiser
  • Publication number: 20060135592
    Abstract: The invention relates to indolinone compounds of formula (I), wherein Y and R1 to R8 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
    Type: Application
    Filed: December 16, 2005
    Publication date: June 22, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Steffen Steurer, Ralph Brueckner, Bernd Krist, Bodo Betzemeier, Frank Hilberg, Armin Heckel, Gerald Roth, Joerg Kley, Thorsten Lehmann-Lintz
  • Publication number: 20060100254
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in Claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: October 5, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel